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Interesting activity has been reported by combining chemotherapy with cetuximab. An alternative approach for blocking EGFR
function has been the development of small-molecule inhibitors of tyrosine kinase domain such as gefitinib. We designed a
multicentre phase II study in advanced colorectal cancer combining gefitinibþFOLFOX in order to determine the activity and to
relate EGFR expression and gene amplification and NF-kB activation to therapeutic results. Patients received FOLFOX-4 regimen plus
gefitinib as first-line treatment. Tumour samples were analysed for EGFR protein expression by immunohistochemical analysis and
for EGFR gene amplification by fluorescence in situ hybridisation (FISH), chromogenic in situ hybridisation (CISH) and NF-kB activation.
Forty-three patients were enrolled into this study; 15 patients experienced a partial response (response rate¼34.9%), whereas other
12 (27.9%) had a stable disease. Median progression-free survival (PFS) was 7.8 months and median overall survival (OS) was 13.9
months. We did not find any relationship with EGFR overexpression, gene amplification, while NF-kB activation was associated with a
resistance to therapy. Gefitinib does not seem to increase the activity of FOLFOX in advanced colorectal cancer even in patients
overexpressing EGFR or with EGFR amplification. Furthermore, while NF-kB activation seems to predict resistance to chemotherapy
as demonstrated ‘in vitro’ models, gefitinib does not overcome this mechanism of resistance, as reported for cetuximab.
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FOLFOX is a generally recognised first-line chemotherapy for
metastatic colorectal cancer. Patients receiving this combination
chemotherapy achieved a 50% response rate, with a time to
progression (TTP) of 9 months and an overall survival of 14
months (de Gramont et al, 2000; Goldberg et al, 2004; Colucci et al,
2005; Meyerhardt and Mayer, 2005).
Recently, interesting activity has been reported by combining
FOLFOX or FOLFIRI with EGFR inhibitors. Epidermal growth
factor receptor has been demonstrated to be overexpressed in
about 70–80% of colorectal tumours and its overexpression is
associated with a worse prognosis (Laskin and Sandler, 2004).
Epidermal growth factor receptor inhibition may be obtained
by blocking the extracellular part of the receptor (Ellis and Hoff,
2004). Cetuximab, a monoclonal antibody, has been demonstrated
to produce a 10% response rate in monotherapy and a 20% when
combined with irinotecan even in patients refractory to this drug
(Cunningham et al, 2004; Lenz et al, 2006).
An alternative approach for blocking EGFR function in cancer
cells has been the development of small molecules able to interfere
with the enzymatic activity of the ligand-activated EGFR (Ellis and
Hoff, 2004). Gefitinib is a potent small-molecule inhibitor of
tyrosine kinase domain of EGFR. It has demonstrated activity in
non-small-cell lung cancer (Cohen et al, 2004). It is orally available
and is an attractive therapeutic option in colorectal cancer
patients. In fact, preclinical data demonstrated a synergism
between gefitinib and oxaliplatin and thymidilate synthetase
inhibitors (Ciardiello et al, 2000; Xu et al, 2003; Van Schaeybroeck
et al, 2005).
Phase I studies showed the feasibility and the safety of the
combination of gefitinib with FOLFOX (Kindler et al, 2005).
Based on these premises, we initiated a multicentre phase II
study in advanced colorectal cancer, combining gefitinib with
FOLFOX in order to determine the activity of such a combination
and to relate EGFR expression and gene amplification to
therapeutic results, as well as if resistance to chemotherapy
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sinduced by NF-kB activation may be overcome by gefitinib, as it
happens for cetuximab.
PATIENTS AND METHODS
Patients were considered eligible for this study if they were older
than 18 years of age and had histologically confirmed metastatic
colorectal adenocarcinoma. Patients were not allowed to receive
any kind of prior treatment for their metastatic disease. Other
eligibility criteria included measurable disease by Response
Evaluation Criteria in Solid Tumors Group (RECIST) criteria, no
prior exposition to EGFR inhibitors, an Eastern Cooperative
Oncology Group (ECOG) performance status 0–1, adequate blood,
renal and liver function. Analysis of tumour EGFR status was not
required for inclusion in this study. The treatment protocol was
approved by local Ethical Committees. This study was sponsored
by AstraZeneca (study number 1839IL/0119).
Treatment
Initially a cohort of five patients received standard doses of
FOLFOX-6 with oxaliplatin at the dose of 100mgm
 2 in
combination with 250mg of gefitinib daily. After five patients
were treated initially, we decided to expand the cohort to 42
patients, administering FOLFOX-4 at dosages previously published
(oxaliplatin 85mgm
 2) (Andre et al, 1999) due to a better profile
of toxicity and tolerability.
Gefitinib at the dose of 250mg has been taken once a day, every
day about the same time. It could be taken with or without food. If
the patients forgot to take a dose, they took the last missed dose as
soon as they remembered, as long as it was at least 12h before the
next dose is due.
All toxicities were graded according to the NCI-CTC version 2.0.
Retreatment at the start of each cycle required adequate
haematologic function and resolution of all toxicities of CTC
grade 2 or more.
Treatment was continued until development of progressive
disease or unacceptable toxicity, withdrawal of patients consent or
decision to perform surgical resection of disease.
Evaluation
Baseline tumour measurements by computed tomography were
obtained within 28 days before study treatment was started.
Physical examination, including medical history, laboratory
studies and assessment of performance status, were conducted at
the beginning of each 2-week cycle. Patients were asked to keep a
diary of daily gefitinib ingestion and record their experience of
nausea and diarrhoea.
Tumour response was evaluated approximately every 8 weeks
by computed tomography imaging and tumour measurement per-
formed using RECIST criteria.
Statistical analysis
Fleming’s method was used to calculate the number of patients
required (O’Brien and Fleming, 1979).
A sample size of 42 patients is sufficient to give an 80%
probability of rejecting a baseline response rate of 50% with an
exact 5% one-sided significance test when the true response is at
the clinically relevant rate of 70%. The hypothesis that the
response rate is equal or less than the baseline is rejected if 27 or
more responses are observed out of the 42 patients. Using the
methods of A’Hearn (2004), the exact size and power of this test
are 4.4 and 83.6%, respectively.
The baseline response rate used for the null hypothesis has been
set at 50%. Rejecting the null hypothesis indicates that the activity
of the combination is at least similar to that observed using
the FOLFOX regimen alone, and therefore that the addition
of gefitinib does not compromise the activity of FOLFOX. In the
absence of gefitinib, the proposed FOLFOX regimen produces
response rates ranging of approximately 50% in the first-line
setting, with median progression free survival of 9 months. The
addition of gefitinib to FOLFOX is expected to increase the
response rate to above 65%. However, the FOLFOX regimen is
associated with toxicity, with grade 3–4 neutropaenia observed in
42% of patients, grade 3–4 diarrhoea and grade 3 neurosensory
toxicity in 18%. In this study there is a potential for overlapping
toxicity, and therefore a higher baseline response rate has not been
used to limit the number of patients exposed to the treatment
before obtaining further data on safety and some preliminary
information on activity.
Immunohistochemical analysis and gene amplification
Tumour samples, formalin-fixed and paraffin-included, were
analysed for EGFR protein expression by immunohistochemical
analysis and for EGFR gene amplification by fluorescence in situ
hybridisation (FISH) and chromogenic in situ hybridisation
(CISH).
Immunohistochemistry The immunohistochemical study was
performed and graded using kit EGFR PharmaDxt (DakoCytomation,
Carpinteria, CA, USA) according to the manufacturer’s instructions as
previously published (Scartozzi et al, 2004).
The EGFR-positive immunostained areas were identified for
creation of the section treated with FISH and CISH technique; in
addition areas at random were selected in negative tumour for
EGFR immunostain.
FISH analysis of EGFR gene copy number
Analysis of EGFR amplification was performed by using the
standard with the dual-colour EGFR Spectrum Oranget/CEP7
s
Spectrum Greent probe (Visys, Downers Grove, IL USA). In brief,
paraffin sections were deparaffinised, dehydrated in ethanol and
air-dried. After treatment in 0.05% pepsin/0.1 N HCl for 45min at
371C, the sample were aged in 0.1% NP-40/2 SSC (standard
saline citrate solution) for 10min at 371C and their DNA was
denatured by treatment in 70% formamide/2 SSC for 4min at
851C. A measure of 5ml of the probe solution was then placed on a
glass slide with a coverslip. The sample slides were hybridised
overnight at 371C and washed, before in 0.4 SSC/0.3% NP-40
at 731C for 2min. Nuclei were counterstained with 40,6-diamino-
2-phenylindole dihydrochloride and p-phenylenediamine in
phosphate-buffered saline (PBS) and glycerol (DAPI II) (Vysis,
Downers Grove, IL, USA). Each FISH assay included normal breast
tissue sections, as negative control, and sections of breast cancer
previously confirmed to have amplification of EGFR as positive
control.
Analyses were performed using a fluorescence microscope
(Nikon Optphot-2 and Quips Genetic Workstation) equipped with
the Tripple Bandpass Filter set (Vysis) for DAPI II, SpectrumOrange
and SpectrumGreen and Filter sets specific to SpectrumOrange and
SpectrumGreen.
Only individual and well-delineated cells were scored; over-
lapping cells were excluded from the analysis. At least 60 cells were
scored for each case and control sample.
Each tumour was assessed by the average and the maximum
numbers of the copies of EGFR gene per cell, and the average
EGFR/chromosome 7 copy number (CEP7) ratio.
Amplification was defined as ratio of EGFR signals to
chromosome 7 centromere signals of 2 or more.
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Chromogenic in situ hybridisation for the EGFR gene was
performed according to the manufacturer’s instructions (Zymed
Laboratories Inc., South San Francisco, CA, USA).
Briefly, the sections of the formalin-fixed and paraffin-
embedded tissue were incubated at 551C overnight. The slides
were deparaffinised in xylene and graded ethanols; heat pretreat-
ment was carried out in the pretreatment buffer (Zymed
Laboratories Inc.) at 961C for 15min.
The tissue was digested with pepsin for 10min at room
temperature, successively was washed with deionised water,
dehydrated with graded ethanol and air-dried.
After application of Zymed Spot-Light
s oligoxigenin labelled
EGFR probe (Zymed Laboratories Inc.), the slides were cover-
slipped and edges sealed with rubber cement. The slides were
heated at 921C for 5min, followed by overnight incubation at 371C
using moisturised chamber.
Post-hybridisation wash was performed the next day, followed
by immunodetection using the CISHt polymer detection kit
(Zymed Laboratories Inc.).
The CISH signals were seen as dark brown dots and counted in
at last 100 nuclei with a light microscope using  40 objective;
only individual and well-delineated cells were scored, and over-
lapping cells were excluded from the analysis. Also the average
gene copies per nucleus for each tissue sections were calculated.
NF-kB
Nuclear factor-kB was evaluated with an immunohistochemical
technique on 3- to 5-mm-thick tissue sections obtained from
paraffin-embedded specimens fixed in 10% (v/v) neutral buffered
formalin.
The sections were deparaffinised in xylene, rehydrated in graded
ethanol, washed in PBS and heated in microwave at 981C, with
EDTA buffer (1mM; pH 8).
Peroxide blocking was performed with 0.3% H2O in methanol at
room temperature for 30min.
The mouse monoclonal antibody raised against amino acids 1–
286 of NF-kB p65 of human origin was used (1:150 dilution; Santa
Cruz Biotechnology, Inc, Santa Cruz, CA, USA) and incubated for
1h at room temperature.
Incubation with the secondary antibody (EnVision System
s;
DakoCytomation, Carpinteria, CA, USA/HRP) was performed for
30min, followed by application of diaminobenzidine chromogen
for 5min. Subsequently, the slides were counterstained with
Meyer’s haematoxylin for 1min, dehydrated in a graded series of
alcohol, treated with xylene and coverslipped.
The slides were evaluated by light microscopy independently by
two pathologists.
Nuclear factor-kB expression was detected as nuclear and
cytoplasmic brown staining of neoplastic cell, with various
intensity. Positivity of the tumour for NF-kB expression was
defined as only distinct nuclear immunostaining, which is
considered as activated NF-kB, and is quantified by a percentage
score (range 0–100).
The lymphocytes within the tissue sections were used as positive
internal controls, which showed positive nuclear staining in all
runs.
The negative control was used during optimisation of the
method and did not show any staining.
RESULTS
Baseline characteristics
Between October 2002 and September 2004, 43 patients were
enrolled into this study. Although four patients discontinued
chemotherapy before completion of two cycles and were lost to
follow-up, all 43 patients enrolled are included in the toxicity and
efficacy analyses, on the basis of intention-to-treat.
The baseline characteristics of the 43 patients are listed in
Table 1.
Treatment administration
The mean duration of trial therapy was 26.07 weeks (range
0.14–83.43 weeks).
Activity
The primary activity end point for this study was objective
response rate. By intent-to-treat analysis, 15 patients experienced a
partial response (response rate¼34.9%), whereas other 12 patients
(27.9%) had a stable disease for at least four cycles (Table 2). The
secondary efficacy end points were progression-free survival (PFS)
and overall survival (OS). The median PFS was 7.8 months (95%
CI: 6.7–10 months) (Figure 1). The median OS for all the patients
was 13.9 months (95% CI: 11.2–19.9 months) (Figure 2).
Toxicities
The toxicities of the study regimen represented a secondary end
point. Thirty-five out of 43 patients (81.4%) expressed some types
of grade 3 or 4 toxicities. Neutropaenia and diarrhoea were
the most common side effects. Additional grade 3–4 toxicities
included transaminase increase (three patients: in one patient
related to gefitinib, in one patient related to FOLFOX and in one
Table 1 Baseline characteristics of patients
Characteristics n
No. of patients 43
Median age, years (range) 60 (35–75)
Sex
Male 23 (53.5%)
Female 20 (46.5%)
Performance status
0 30 (69.8%)
1 13 (30.2%)
Received prior adjuvant therapy
Yes 9 (20.9%)
No 34 (79.1%)
Metastatic sites
1 site 21 (48.8%)
41 site 22 (51.2%)
Table 2 Activity of the treatment
Parameter n (%)
Partial response 15/43 (34.9%)
Stable disease 12/43 (27.9%)
Progressive disease 12/43 (27.9%)
Median response duration 5.3 months (range: 0.9–20.9)
Median PFS 7.8 months (95% CI: 6.7–10)
Median OS 13.9 months (95% CI: 11.2–19.9)
CI¼confidence interval; OS¼overall survival; PFS¼progression-free survival.
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spatient related to both gefitinib and FOLFOX), leukopaenia related
to FOLFOX (three patients), mucositis (two patients: in one patient
related to FOLFOX and in one patient related to both gefitinib
and FOLFOX) dermatitis or dry skin attributable to gefitinib in
one patient and grade 3 peripheral neuropathy attributable to
oxaliplatin in one patient. The most common toxicities for all
causes are listed in Table 3.
Immunoistochemistry analysis and gene amplification
Results of EGFR gene analysis by FISH and CISH and NF-kB
expression related to clinical response are summarised in Table 4.
Data on 20 patients were available for biological analysis. Nuclear
factor-kB was activated in four out of five patients who progressed,
while it was not activated in all the 10 patients who achieved a PR.
The results were statistically significant (Po0.05).
Epidermal growth factor receptor was overexpressed in four out
of the five patients who progressed, and in six of the 10 patients
who had a partial response, but the results were not statistical
significant.
Epidermal growth factor receptor was not amplificated in nine
out of the 10 patients who achieved a partial response, and in all
the five patients who progressed.
DISCUSSION
The number of available chemotherapy regimens against meta-
static colon cancer is rapidly growing. Oxaliplatin or irinotecan in
combination with infusional 5FU has been shown to be effective in
achieving an improved response and TTP compared with 5FU/LV
in colorectal cancer (Grothey et al, 2004).
The high level of EGFR response in colorectal cancer specimens
has sparked great interest in using this target to develop more
direct and specific therapies (Baselga and Arteaga, 2005). To date,
positive results with EGFR inhibitors have only been reported for
the monoclonal antibody cetuximab. Small-molecule inhibitors of
EGFR have recently been tested in combination with chemother-
apy in second-line treatment in colorectal cancer. Both gefitinib
and erlotinib in combination with FOLFOX or capecitabine and
oxaliplatin showed interesting results obtaining higher response
rates than those expected with chemotherapy alone. In spite of the
lack of benefit for the addition of gefitinib or erlotinib to standard
chemotherapy in non-small-cell lung cancer, the results obtained
in second-line therapy of colorectal cancer are a strong rationale to
move this combination to first line treatment (Kuo et al, 2005;
Meyerhardt et al, 2006).
In this multi-institutional phase II study of the combination of
FOLFOX with gefitinib for previously untreated colorectal cancer
patients, we observed a response rate of 34.9% and a median PFS
of 7.8 months. The median survival for this population of patients
was 13.9 months.
Our findings do not compare favourably with similar regimens
in first line treatment. In fact, regimens with infusional 5FU and
oxaliplatin result in similar response rates and TTP, suggesting
that adding gefitinib to FOLFOX does not improve the efficacy of
this regimen. These negative results may be due to a lack of
efficacy of small molecules inhibitors of EGFR in combination with
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Figure 2 Kaplan–Meier plots for overall survival.
Table 3 Grade 3–4 toxicities (all causes)
Toxicity All grades (%) Grades 3–4 (%)
Neutropaenia 26 (60) 18 (42)
Thrombocytopaenia 14 (33) —
Diarrhoea 28 (65) 13 (30)
Mucositis 10 (23) 2 (5)
Leukopaenia 9 (21) 3 (7)
Transaminase increase 8 (19) 3 (7)
Neuropathy 11 (25) 1 (2.3)
Dermatitis 16 (37) 1 (2.3)
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Figure 1 Kaplan–Meier plots for progression free survival.
Table 4 Available biological data on 20 patients
NF-kB activation
Yes (4) No (16)
PR 0 10 Po0.05
SD — 5 Po0.05
PD 4 1 Po0.05
EGFR overexpression
Yes (11) No (9)
PR 6 4 P¼NS
SD 1 4 P¼NS
PD 4 1 P¼NS
EGFR amplification
Yes (3) No (17)
PR 1 9
SD 2 3
PD — 5
EGFR¼epidermal growth factor receptor; NF-kB¼nuclear factor-kB; NS¼non-
significant; PR¼partial response; PD¼progressive disease; SD¼stable disease.
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schemotherapy as in colorectal cancer or to the lack of patient
selection (Giaccone et al, 2004; Herbst et al, 2004; Messersmith
et al, 2004).
A recent study by Zampino and co-workers also evaluated the
combination FOLFOX-6 and gefitinib in a phase II trial including
56 patients. The results showed a higher response (complete
response¼5.36%; partial response¼66.1%) and a higher disease
control (91.1%; 95% CI¼80.4–97%). Due to the rather small
numbers of patients and to the nature of the trial (phase II), in our
opinion the differences between the above mentioned and our
results are likely due to chance. Nevertheless, a comment could be
addressed: in the trial of Zampino and co-workers, patients were
enrolled if they had at least 20% cancer cells positive for EGFR,
while in our trial only 1% of EGFR positivity was required as per
standard practice (Zampino et al, 2007).
No biological correlative studies were able to demonstrate a
predictive factor for cetuximab therapy activity. Nevertheless, we
analysed EGFR overexpression and amplification and NF-kB activa-
tion in 20 out of 43 patients receiving gefitinib and chemotherapy.
Table 4 summarises these findings. While EGFR overexpression
determined by immunohistochemistry is not able to predict response
to cetuximab, EGFR amplification was reported to be a good indicator
of sensitivity to cetuximab in colorectal cancer. Nuclear factor-kB
activation results in an increased resistance to chemotherapy, and the
administration of an EGFR inhibitor seems to be able to revert this
resistance (Sclabas et al, 2003).
In our study, we did not find any relationship between EGFR
overexpression and response. In spite of the experience of Moroni
et al (2005) where about 30% of tumours presented an EGFR
amplification, we did not find it in any of our patients.
Similar data were reported by Garufi et al (2006) in 70 colorectal
cancer patients. In fact, amplification was found in three patients
only. Furthermore, Lenz et al (2006) reported that EGFR
amplification is not related to response to cetuximab, questioning
the role of EGFR amplification in the prediction of clinical activity
of EGFR inhibitors.
The NF-kB transcriptional factor is constitutively activated in
several tumours included colorectal cancer. Furthermore, it is
activated by chemotherapy and it represents one of the most
important mechanism of cell survival in response to chemotherapy
resulting in resistance to treatment (Lind et al, 2001; Rakitinat
et al, 2003; Sclabas et al, 2003; Guo et al, 2004; Voboril et al, 2004;
Karin, 2006). In our study, activation of NF-kB was present in four
cases. These patients did not respond to treatment, while all the
patients with no NF-kB activation presented an objective response.
This factor seems to be able to predict resistance to a treatment
with FOLFOX and the addition of gefitinib does not overcome
this resistance, as some preclinical data suggested for cetuximab
(Sclabas et al, 2003). Our data are too limited to draw any
definitive conclusion; nevertheless in our experience gefitinib does
not increase the activity of FOLFOX combination in advanced
colorectal cancer even in patients overexpressing EGFR or with
EGFR amplification. Furthermore, while NF-kB activation seems to
predict resistance to chemotherapy as demonstrated in ‘in vitro’
models, in our trial, although the small numbers, gefitinib does not
overcome this mechanism of resistance as reported for cetuximab.
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